UK markets close in 1 hour 31 minutes

ProKidney Corp. (PROK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3994-0.0006 (-0.03%)
As of 09:59AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4000
Open2.3200
Bid2.3400 x 100
Ask2.4300 x 100
Day's range2.2750 - 2.3994
52-week range1.1200 - 13.5100
Volume78,205
Avg. volume661,208
Market cap1.811B
Beta (5Y monthly)1.29
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

    Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as Senior Vice President of Global Clinical Operations having over 30 years of experience in clinical trial execution WINSTON-SALEM, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutic

  • GlobeNewswire

    ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

    WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. “We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential

  • GlobeNewswire

    ProKidney to Participate in Jefferies Biotech on the Bay Summit

    WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024. The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies